Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2925 Target Snapshot

Potassium voltage-gated channel subfamily KQT member 5 · SINGLE PROTEIN · Homo sapiens

38Compounds
12Assays
1Approved Drugs
13.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Protein identity stays anchored to UniProt Q9NR82. Use UniProt Q9NR82 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt Q9NR82 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Potassium voltage-gated channel subfamily KQT member 5 as ChEMBL target CHEMBL2925, mapped to UniProt Q9NR82. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Potassium voltage-gated channel subfamily KQT member 5
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL2925
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
Q9NR82
Potassium voltage-gated channel subfamily KQT member 5
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Potassium voltage-gated channel subfamily KQT member 5 is the right protein anchor across sources, using UniProt Q9NR82 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelPotassium voltage-gated channel subfamily KQT member 5
UniProt AccessionQ9NR82
Component TypeProtein
Sequence Length932 aa

Potassium voltage-gated channel subfamily KQT member 5

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Potassium voltage-gated channel subfamily KQT member 5, mapped to UniProt Q9NR82. Sequence length is 932 aa.

Mapped IDQ9NR82
Review namePotassium voltage-gated channel subfamily KQT member 5
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

1
Approved
1
Phase III
Assay Mix

Activity Type Distribution

EC5013.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL4457044 6.46 EC50 350.0 Preclinical
CHEMBL4549229 6.27 EC50 540.0 Preclinical
CHEMBL41355 6.1 EC50 800.0 Approved
CHEMBL4545892 5.97 EC50 1070.0 Preclinical
CHEMBL5185685 5.97 EC50 1060.0 Preclinical
CHEMBL4438770 5.86 EC50 1370.0 Preclinical
CHEMBL4588394 5.78 EC50 1680.0 Preclinical
CHEMBL266510 5.62 EC50 2400.0 Clinical
CHEMBL4450214 5.61 EC50 2430.0 Preclinical
CHEMBL4458793 5.42 EC50 3780.0 Preclinical
Distribution

pChEMBL Value Distribution

4
5.0
6
5.5
3
6.0
0
6.5
0
7.0
0
7.5
0
8.0
0
8.5
0
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

EZOGABINE
CHEMBL41355
Approved 2011
Assay Landscape

Assay Landscape

13
Total Assays
10
Tested Compounds
3
Assay Types
Binding — 10 assays, 10 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 9 9 5.7
single protein format 1 1 5.6
ADME — 2 assays, 3 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 2 3 6.2
Functional — 1 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 1 0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine